Position in ZYME
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$1,873,192
+$468,273 QoQ
Shares Held
71,660
+27.7% QoQ
Ownership
0.101%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#71
of 203 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 94%
Shared 0%
None 6%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Dana Investment Advisors, Inc. holds $43,128,971 across 12 Biotechnology names. ZYME ranks #7 (4.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
57,520 | $18,181,496 | |
| 2 | AXSM |
Axsome Therapeutics, Inc.
|
22,850 | $5,592,994 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
7,719 | $4,813,105 | |
| 4 | TGTX |
Tg Therapeutics, Inc.
|
42,012 | $2,308,139 | |
| 5 | VKTX |
Viking Therapeutics, Inc.
|
57,854 | $2,256,884 | |
| 6 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
3,677 | $1,974,365 | |
| 7 | ZYME |
Zymeworks Inc.
This page
|
71,660 | $1,873,192 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
23,272 | $1,845,236 |
All Filings in ZYME
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,873,192 | 71,660 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $1,404,919 | 56,107 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $1,272,212 | 48,318 | Shares | Sole | 2026-02-05 | |
| No filing history on record for this holder in this stock. | ||||||